Nemunaitis J
Hematopoiesis Program, Western Pennsylvania Cancer Institute, West Penn Hospital, Pittsburgh 15224.
Ann Med. 1993 Feb;25(1):25-9. doi: 10.3109/07853899309147853.
Clinical application of colony-stimulating factors (CSFs) such as recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) are advancing rapidly now that these factors are approved as indicated therapy in patients with chemotherapy-induced neutropenia, patients undergoing autologous bone marrow transplantation (BMT) and patients who develop graft failure after BMT. Novel CSFs are also being explored for potential clinical application in situations not as significantly affected by rhG-CSF or rhGM-CSF. Studies determining unique effects of novel factors, combinations of factors and combinations with peripheral blood progenitor cell fusions which may lead to future clinical applications of CSFs will be reviewed.
集落刺激因子（CSF）如重组人粒细胞集落刺激因子（rhG-CSF）和重组人粒细胞巨噬细胞集落刺激因子（rhGM-CSF）的临床应用正在迅速发展，因为这些因子已被批准用于化疗引起的中性粒细胞减少症患者、接受自体骨髓移植（BMT）的患者以及BMT后发生移植失败的患者的指定治疗。新型CSF也正在探索其在受rhG-CSF或rhGM-CSF影响不显著的情况下的潜在临床应用。将对确定新型因子、因子组合以及与外周血祖细胞融合的组合的独特作用的研究进行综述，这些研究可能会导致CSF在未来的临床应用。
